Yahoo Finance • last month
The U.S. market has recently experienced a surge, with major indices like the Dow Jones reaching record highs following Federal Reserve Chair Jerome Powell's indication of potential interest rate cuts. In this context, the allure of penny... Full story
Yahoo Finance • 2 months ago
– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference... Full story
Yahoo Finance • 2 months ago
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close o... Full story
Yahoo Finance • 3 months ago
[Top Prospects Most Profitable Stock Market Best Investments 3d Illustration] iQoncept/iStock via Getty Images UBS analysts listed top and bottom-ranked stocks based on a key set of drivers for equities, they named REVS. UBS’s REVS frame... Full story
Yahoo Finance • 12 months ago
We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers.In this article, we are going to take a look at where Coherus BioSciences, Inc. (NASDAQ:CHRS) stands against the other Worst 52-Week Low S... Full story
Yahoo Finance • last year
We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Coherus BioSciences, Inc. (NASDAQ:CHRS) stands against the other worst 52-week low sto... Full story
Yahoo Finance • 2 years ago
growth curve Small-cap stocks have been under pressure ever since the Federal Reserve started hiking interest rates in the first quarter of 2022. As a result, scores of companies in this category sport rock-bottom valuations right now. Wi... Full story
Yahoo Finance • 2 years ago
Coherus BioSciences, Inc. REDWOOD CITY, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 20, 2023, the compensation committee of the Co... Full story
Yahoo Finance • 2 years ago
Coherus BioSciences, Inc. – NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy; LOQTOR... Full story
Yahoo Finance • 2 years ago
Coherus BioSciences, Inc. REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that McDavid Stilwell, Chief Financial Officer (CFO), has resigned from the company to pu... Full story
Yahoo Finance • 2 years ago
Improved confidence in the supply chains ability to support strong demand in the aircraft industry has led to a positive outlook for Boeing (NYSE:BA). RBC Capital Markets analyst Ken Herbert has increased the price target for Boeing to $27... Full story
Yahoo Finance • 2 years ago
REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences: Truist Securities BioPharma Sympo... Full story
Yahoo Finance • 2 years ago
REDWOOD CITY, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences: Citi's 2023 18th Annual BioPharm... Full story
Yahoo Finance • 2 years ago
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF) (“Surface”), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today anno... Full story
Yahoo Finance • 2 years ago
Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment. The Surfac... Full story
Yahoo Finance • 2 years ago
REDWOOD CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock. In addition... Full story
Yahoo Finance • 3 years ago
Coherus BioSciences, Inc. REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences in March. 43... Full story
Yahoo Finance • 3 years ago
Coherus BioSciences, Inc. REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be released after mark... Full story
Yahoo Finance • 3 years ago
REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Ja... Full story
Yahoo Finance • 3 years ago
Scout Investments, an affiliate of Carillon Tower Advisers, an investment management company, released its “Carillon Scout Small Cap Fund” third quarter 2022 investor letter. You can download a copy of the same here. The fund underperforme... Full story